EUROPE ATOPIC DERMATITIS DRUGS MARKET FORECAST 2019-2027
Europe Atopic Dermatitis Drugs Market by Route of Administration (Roa) (Topical, Oral, Injectable) by Drug Class (Topical Antibiotics, Topical Antihistamines, Topical Corticosteroids, Topical Moisturizers/emollients, Topical Calcineurin Inhibitors, Immunomodulators, Off-label Therapies, Systemic Agents, Pde-4 Inhibitor, Interleukin Inhibitor) by Geography
The European market for atopic dermatitis drugs is expected to have a CAGR of 3.30% over the forecast period of 2019-2027. The prevalence of the disease is because of factors such as age and climate. It affects up to xx% of the population in northern Europe, where there is less sunshine, while in the coastal region of southern Europe, very few people are affected.
The major areas covered under this report are Germany, France, Russia, the United Kingdom. The other countries have been clubbed as Rest of Europe. In Europe, the UK market holds the maximum share in the use of atopic dermatitis drugs. This particular market is driven by the increase of allergic population. European researchers who are trying to find a novel way to treat this disease have reported that the occurrence of atopic dermatitis is seen more in areas that are highly industrialized. In the UK alone, atopic dermatitis has increased two to three times in the past three decades. The common misconception of it being a childhood disease has been scrapped as reports have shown that even adults suffer from it due to simple reasons like a food allergy.
Prominent companies in the European atopic dermatitis drugs market include Allergan Plc, Aqua Pharmaceuticals (An Almirall Company), Astellas Pharma Inc., Bayer Ag, Biofrontera Ag, Bristol-Myers Squibb, Stiefel Laboratories, Inc, Encore Dermatology, Galderma Sa, Leo Pharma, Meda Pharmaceuticals (Mylan N.V.), Novartis Ag, Pfizer, Regeneron Pharmaceuticals, Sanofi Sa, and Valent Pharmaceutical Inc.
To request a free sample copy of this report, please complete the form below:
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.
- RESEARCH SCOPE
- STUDY GOALS
- SCOPE OF THE MARKET STUDY
- WHO WILL FIND THIS REPORT USEFUL?
- STUDY AND FORECASTING YEARS
- RESEARCH METHODOLOGY
- SOURCES OF DATA
- SECONDARY DATA
- PRIMARY DATA
- TOP-DOWN APPROACH
- BOTTOM-UP APPROACH
- DATA TRIANGULATION
- SOURCES OF DATA
- EXECUTIVE SUMMARY
- MARKET SUMMARY
- KEY FINDINGS
- TOPICAL ROUTE OF ADMINISTRATION HOLDS MAJORITY OF THE OVERALL MARKET SHARE
- INTERLEUKIN INHIBITOR MARKET IS ANTICIPATED TO GENERATE HIGHEST REVENUE
- MARKET DETERMINANTS
- MARKET DRIVERS
- GROWING PREVALENCE OF FOOD ALLERGIES EXACERBATING ATOPIC DERMATITIS
- GROWING FOCUS ON SYSTEMATIC THERAPIES
- INCREASING USE OF PHARMACOLOGICAL PRODUCTS IN DEVELOPING COUNTRIES
- MARKET RESTRAINTS
- STRINGENT REGULATIONS FOR PRODUCT APPROVAL
- GENERIC COMPETITION
- MARKET OPPORTUNITIES
- INCREASING M&A LEADING TO MARKET CONSOLIDATION
- LAUNCH OF FIRST BIOLOGIC FOR ATOPIC DERMATITIS
- GROWING FOCUS ON NOVEL DRUGS
- MARKET CHALLENGES
- BLACK BOX WARNING FOR ELIDEL AND PROTOPIC
- HIGHLY GENERICIZED MARKET
- POOR PATIENT ADHERENCE DUE TO INADEQUATE INFORMATION ON DRUG USAGE
- MARKET DRIVERS
- MARKET SEGMENTATION
- MARKET BY ROUTE OF ADMINISTRATION (ROA) 2019-2027
- TOPICAL
- ORAL
- INJECTIBLES
- MARKET BY DRUG CLASS 2019-2027
- TOPICAL ANTIBIOTICS
- TOPICAL ANTIHISTAMINES
- TOPICAL CORTICOSTEROIDS
- TOPICAL MOISTURIZERS/EMOLLIENTS
- TOPICAL CALCINEURIN INHIBITORS
- IMMUNOMODULATORS
- OFF-LABEL THERAPIES
- SYSTEMIC AGENTS
- PDE4 INHIBITOR
- INTERLEUKIN INHIBITOR
- MARKET BY ROUTE OF ADMINISTRATION (ROA) 2019-2027
- KEY ANALYTICS
- PORTER’S FIVE FORCES ANALYSIS
- THREAT OF NEW ENTRANTS
- THREAT OF SUBSTITUTE
- BARGAINING POWER OF SUPPLIERS
- BARGAINING POWER OF BUYERS
- THREAT OF COMPETITIVE RIVALRY
- OPPORTUNITY MATRIX
- PIPELINE ANALYSIS
- LEGAL, POLICY AND REGULATORY ISSUES
- PORTER’S FIVE FORCES ANALYSIS
- GEOGRAPHICAL ANALYSIS
- EUROPE
- GERMANY
- FRANCE
- THE UNITED KINGDOM
- RUSSIA
- ITALY
- REST OF EUROPE
- EUROPE
- COMPANY PROFILES
- ALLERGAN PLC
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SWOT ANALYSIS
- STRATEGIC INITIATIVES
- AQUA PHARMACEUTICALS (AN ALMIRALL COMPANY)
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SWOT ANALYSIS
- ASTELLAS PHARMA INC.
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SWOT ANALYSIS
- STRATEGIC INITIATIVES
- BAYER AG
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SWOT ANALYSIS
- STRATEGIC INITIATIVES
- BIOFRONTERA AG
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SWOT ANALYSIS
- BRISTOL-MYERS SQUIBB
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SWOT ANALYSIS
- STIEFEL LABORATORIES, INC
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SWOT ANALYSIS
- ENCORE DERMATOLOGY
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SWOT ANALYSIS
- STRATEGIC INITIATIVES
- GALDERMA SA
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SWOT ANALYSIS
- STRATEGIC INITIATIVES
- LEO PHARMA
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SWOT ANALYSIS
- STRATEGIC INITIATIVES
- MEDA PHARMACEUTICALS (MYLAN N.V.)
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SWOT ANALYSIS
- STRATEGIC INITIATIVES
- NOVARTIS AG
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SWOT ANALYSIS
- STRATEGIC INITIATIVES
- PFIZER
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SWOT ANALYSIS
- STRATEGIC INITIATIVES
- REGENERON PHARMACEUTICALS
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SWOT ANALYSIS
- STRATEGIC INITIATIVES
- SANOFI SA
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SWOT ANALYSIS
- STRATEGIC INITIATIVES
- VALENT PHARMACEUTICAL INC.
- COMPANY OVERVIEW
- PRODUCT PORTFOLIO
- SWOT ANALYSIS
- ALLERGAN PLC
TABLE LIST
TABLE 1 EUROPE ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
TABLE 2 RECENT MERGERS AND ACQUISITIONS IN ATOPIC DERMATITIS DRUGS MARKET
TABLE 3 EUROPE ATOPIC DERMATITIS DRUGS MARKET BY ROA 2019-2027 ($ MILLION)
TABLE 4 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL ROA 2019-2027 ($ MILLION)
TABLE 5 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN ORAL ROA 2019-2027 ($ MILLION)
TABLE 6 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN INJECTIBLES ROA 2019-2027 ($ MILLION)
TABLE 7 EUROPE ATOPIC DERMATITIS DRUGS MARKET BY DRUG CLASS 2019-2027 ($ MILLION)
TABLE 8 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL ANTIBIOTICS 2019-2027 ($ MILLION)
TABLE 9 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL ANTIHISTAMINES 2019-2027 ($ MILLION)
TABLE 10 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL CORTICOSTEROIDS 2019-2027 ($ MILLION)
TABLE 11 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL MOISTURIZERS/EMOLLIENTS 2019-2027 ($ MILLION)
TABLE 12 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN TOPICAL CALCINEURIN INHIBITORS 2019-2027 ($ MILLION)
TABLE 13 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN IMMUNOMODULATORS 2019-2027 ($ MILLION)
TABLE 14 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN OFF-LABEL THERAPIES 2019-2027 ($ MILLION)
TABLE 15 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN SYSTEMIC AGENTS 2019-2027 ($ MILLION)
TABLE 16 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN PDE4 INHIBITOR 2019-2027 ($ MILLION)
TABLE 17 EUROPE ATOPIC DERMATITIS DRUGS MARKET IN INTERLEUKIN INHIBITOR 2019-2027 ($ MILLION)
TABLE 18 PIPELINE PORTFOLIO OF DIABETES DRUGS MARKET
TABLE 19 REGULATORY FRAMEWORK IN ATOPIC DERMATITIS MARKET
TABLE 20 EUROPE ATOPIC DERMATITIS DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)
FIGURE LIST
FIGURE 1 EUROPE ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 2 GERMANY ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 3 FRANCE ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 4 THE UNITED KINGDOM ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
FIGURE 5 RUSSIA ATOPIC DERMATITIS DRUGS MARKET, 2019-2027 ($ MILLION)
FIGURE 6 ITALY ATOPIC DERMATITIS DRUGS MARKET, 2019-2027 ($ MILLION)
FIGURE 7 REST OF EUROPE ATOPIC DERMATITIS DRUGS MARKET 2019-2027 ($ MILLION)
- GEOGRAPHICAL ANALYSIS
- EUROPE
- GERMANY
- FRANCE
- THE UNITED KINGDOM
- RUSSIA
- ITALY
- REST OF EUROPE
- EUROPE
- MARKET SEGMENTATION
- MARKET BY ROUTE OF ADMINISTRATION (ROA) 2019-2027
- TOPICAL
- ORAL
- INJECTIBLES
- MARKET BY DRUG CLASS 2019-2027
- TOPICAL ANTIBIOTICS
- TOPICAL ANTIHISTAMINES
- TOPICAL CORTICOSTEROIDS
- TOPICAL MOISTURIZERS/EMOLLIENTS
- TOPICAL CALCINEURIN INHIBITORS
- IMMUNOMODULATORS
- OFF-LABEL THERAPIES
- SYSTEMIC AGENTS
- PDE4 INHIBITOR
- INTERLEUKIN INHIBITOR
- MARKET BY ROUTE OF ADMINISTRATION (ROA) 2019-2027
To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.